Board of directors
We are a team of seasoned biotechnology professionals with significant experience developing and lauching leading pharmaceutical products.
Rob Etherington is the President/CEO of Clene Nanomedicine, Inc., a Phase 2 clinical-stage biopharmaceutical pursuing drug therapies for Multiple Sclerosis, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s Disease).
Etherington began his pharmaceutical career with a number of sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in a Team Leader position over the drug Lipitor. He left Pfizer in 2000 to be the founding Director of Marketing during the IPO year of Swiss-based, Actelion Pharmaceuticals, focused in cardiopulmonary disease. Actelion was the largest biopharmaceutical company based in the EU until Johnson & Johnson Pharmaceuticals purchased Actelion. Etherington was the first US commercial employee, leading U.S. commercial operations and serving as Chair of the US Commercial Strategic Team, with responsibility for five marketed drugs. As CEO of Clene Nanomedicine, Etherington has raised ~$70M to-date to fund Clene’s drug development efforts. Clene’s first drug, CNM-Au8, is presently in its first Phase 2 clinical human trial, VISIONARY-MS, a clinical study of remyelination in multiple sclerosis patients, and will commence REPAIR-PD and REPAIR-ALS by 2019 in neurodegeneration. A pipeline of other therapeutic nanotherapeutics are presently in preclinical development.
Shalom "Shal" JacobovitzChairman
Shalom “Shal” Jacobovitz is the Chairman of the Clene Board of Directors. Shal is the chief executive officer of CIVI Bio, a privately held biopharmaceutical, and the former CEO of the American College of Cardiology.
In this role at the ACC, Jacobovitz led the ~50,000 member organization in its mission to transform cardiovascular care and improve heart health. Prior to joining the ACC, Jacobovitz served as president of Actelion Pharmaceuticals U.S., a biopharmaceutical company specializing in orphan cardiopulmonary therapies. He has also held positions at F. Hoffmann La Roche, Abbott Canada, Nordic Labs and Marion Merrill Dow — now known as Sanofi — in Canada. Shal earned his Bachelor of Science degree in biology at Western University in Canada.
Robert C. Gay, PhDBoard Member
Robert Gay is the former managing director and the CEO of Huntsman Gay Global Capital, and the former principal and managing director of Bain Capital in Boston, Massachusetts, where he was instrumental in the expansion of Bain Capital and in establishing Bain Capital in Europe. Bob is a former executive vice president of GE Credit Co, former vice president of Kidder Peabody, and a former engagement manager at McKinsey & Company. He also served as part of the economics faculty at Harvard University. Bob is a co-founder of the global microcredit foundation Unitas Labs and a member of the advisory boards for the Forever Young Foundation, KoMart Foundation (Ghana), and the Ascend Alliance. Bob was awarded a PhD in global economics from Harvard University.
John Stevens, MDBoard Member
John Stevens, MD, currently serves as the chairman and CEO of Heartflow, Inc, a provider of noninvasive cardiovascular imaging technology, and as the managing partner of Headwaters Capital Partners. John is also the founder of the nonprofit NGO KaeMe.org, which advocates for orphaned children in Ghana, West Africa. John was a practicing adult and pediatric cardiac surgeon at Stanford University Hospital and Lucile Salter Packard Children’s Hospital in California and earned a medical degree from the Stanford University School of Medicine.
Chad YoungBoard Member
Chad Young has worked in a variety of businesses ranging from small privately-held companies (GeNOsys, Lodestar, Handpiece Rescue) to multinational corporations with revenues in excess of $10B (Textron, Inc.; Bell Helicopter). He has expertise in organizational design and strategy, and in working with C-suite executives and Board of Directors. Chad earned a Masters degree from Brigham Young University.
Ryan LundBoard Member
Ryan Lund is partner at One Enterprises, a private impact investment company. He holds an Oxford University MBA.
Reed N WilcoxBoard Member
Reed Wilcox is the President of Southern Virginia University. Reed co-founded Clene Nanomedicine. Prior to Clene Nanomedicine, President Wilcox was co-founder and senior managing director of General Resonance. Earlier, Reed co-founded The Flagship Group, worked as CEO of The Lifelike Company, served a three-year mission as president of the France Marseille/Toulouse Missions of The Church of Jesus Christ of Latter-day Saints, and was a worldwide partner at The Boston Consulting Group. Reed earned his bachelor degree in economics at Brigham Young University and his JD/MBA from Harvard University.
David T. LisonbeeBoard Member
David T Lisonbee founded 4Life Research, LLC in 1998 and serves as its Chairman of the Board. David brings more three decades of experience in the fields of health education and network marketing to his leadership at 4Life. He and his co-founder wife, Bianca have led 4Life to record growth, with a presence in multiple global markets, including the company being named as number 15 on the Inc. 500’s 2003 list of the fastest-growing companies in the U.S. He was named one of Utah’s Entrepreneurs of the Year, and has secured a record list of patents. David was awarded the I.N. Blokhina Award from the Russian Federation in honor of his commitment to Transfer Factor research, patents, and innovative production methods. He received his MBA degree from Brigham Young University.